@usstocksnews | YouTube | VK Видео | Чат
🔹 Revenue: $15.42B (Est. $15.00B) 🟢; UP +6.6% YoY
🔹 Adj. EPS: $2.97 (Est. N/A); UP +12.1% YoY
🔹 Adj. Gross Margin: 84.4%
Segment Revenue – Immunology:
🔹 Skyrizi: $4.42B (Est. $4.03B) 🟢; UP +62.2% YoY
🔹 Rinvoq: $2.03B (Est. $1.99B) 🟢; UP +41.8% YoY
🔹 Humira: $1.18B (Est. $1.42B) 🔴; DOWN -58.1% YoY
🔹 Total Immunology: $7.63B; UP +9.5% YoY
Segment Revenue – Neuroscience:
🔹 Total: $2.68B; UP +24.2% YoY
🔹 Vraylar: $900M; UP +16.3% YoY
🔹 Botox Therapeutic: $928M; UP +14.1% YoY
🔹 Ubrelvy: $338M; UP +47.1% YoY
🔹 Qulipta: $267M; UP +77.5% YoY
Segment Revenue – Oncology:
🔹 Total: $1.68B; UP +2.6% YoY
🔹 Imbruvica: $754M (Est. $713.4M) 🟢; -9.5% YoY
🔹 Venclexta: $691M; UP +8.5% YoY
🔹 Elahere: $159M; UP +24.2% YoY
Segment Revenue – Aesthetics:
🔹 Total: $1.28B; DOWN -8.1% YoY
🔹 Botox Cosmetic: $692M; DOWN -5.0% YoY
🔹 Juvederm: $260M; DOWN -24.0% YoY
FY25 Guidance (Updated):
🔹 Adj. EPS: $11.88–$12.08 (↑ from $11.67–$11.87) 🟢
🔸 Includes -$0.55/sh impact from IPR&D and milestones
Для обсуждения переходи в чат t.me/USstocksnews_chat
Комментарий генерального директора Роберта А. Майкла:
🔸 «Высокие показатели диверсифицированной платформы роста и обнадеживающая динамика развития позволили нам снова повысить годовой прогноз».
#abbv
